{"id":31378,"date":"2017-02-27T12:21:17","date_gmt":"2017-02-27T12:21:17","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=31378"},"modified":"2020-03-06T12:06:08","modified_gmt":"2020-03-06T12:06:08","slug":"fit-for-purpose-antiretroviral-treatment-optimisation-feb-2017","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/31378","title":{"rendered":"Fit for purpose: antiretroviral treatment optimisation Feb 2017"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-31226\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017-241x300.png\" alt=\"New CROI logo 2017\" width=\"241\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017-241x300.png 241w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/02\/NEW-CROI-LOGO-2017.png 551w\" sizes=\"auto, (max-width: 241px) 100vw, 241px\" \/><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones.<\/strong><\/p>\n<p>These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects.<\/p>\n<p>The ARVs are: dolutegravir (DTG), tenofovir alafenamide (TAF), efavirenz (EFV) 400 mg, and darunavir\/ritonavir (DRV\/r).<\/p>\n<p>Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimsation studies looking to get increased outcomes from reduced doses in low- and middle-income countries.<\/p>\n<p><strong>Fit for Purpose i-Base \u2013 Feb 2017<br \/>\n<\/strong><a href=\"https:\/\/i-base.info\/wp-content\/uploads\/2017\/02\/Fit-for-Purpose-ii-Base-Feb2017.pdf\">https:\/\/i-base.info\/wp-content\/uploads\/2017\/02\/Fit-for-Purpose-ii-Base-Feb2017.pdf<\/a>\u00a0(PDF)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones. These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects. The &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,241,3],"tags":[236],"class_list":["post-31378","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-fit-for-purpose","category-antiretrovirals","tag-croi-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/31378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=31378"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/31378\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=31378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=31378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=31378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}